Nureca
- Market cap
- ₹ 305 Cr.
- P/E
- 63.5x
- P/B
- 1.76x
- 52-week range
- 204 – 376
- ROE
- 1%
- ROCE
- 3%
- Dividend yield
- 0%
- Debt / equity
- 0.01
- Sector
- Healthcare Equipment & Supplies
- Industry
- Medical Equipment & Supplies
- Listed on
- NSE, BSE
About
Nureca Limited is a specialist in home healthcare and wellness products. Its products serve individuals, caregivers and medical practitioners across the globe. It offers a range of products specialized in home-based, non-invasive digital diagnosis and prevention of lifestyle diseases. Its range of products are spread across categories like respiratory wellbeing, physiotherapy, cardiac health monitoring, diabetes detection, mother and childcare and more. Its brands include Dr. Trust, trumom and Dr. Physio. Dr. Trust is a wellness and healthcare brand which provides medical devices and health monitoring solutions. trumom is a mother and childcare brand. Dr. Physio is an ortho and pain management brand. Its chronic devices include home monitoring devices and medical wearables that populate readings to identify health patterns. Its lifestyle products span weighing scales to yoga gear. Dr Trust 360 enables monitoring, analyses, storing and reporting of health data and patterns over time.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Medical Equipment & Supplies: 25 companies →Nureca against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)63.5 against a typical 26.9: pricier than most peers (1st = cheapest).21st of 25
- Sales growth+55.1% against a typical +21.5% from a year earlier.5th of 18
- Profit growth+11.6% against a typical +13.4% from a year earlier.9th of 16
- Share price, 3 months−7.9% against a typical −7.9%.12th of 23
- Size₹ 305 Cr. market value against a typical ₹ 238.1 Cr. (1st = largest).12th of 24
Latest announcements
Exchange filings and their impact on the company.
- 55% Q2 revenue jump and 60% H1 profit jump point to much larger scale and earnings over next year.
Nureca reported strong Q2 FY27 results with consolidated revenue of Rs 58.5 crore, up 55% from a year ago, and net profit of Rs 4.05 crore. For the first half, revenue was Rs 98.9 crore and net profit was Rs 7.1 crore, already well above last full year. The growth comes with higher inventories, receivables and ongoing capex, but points to much larger sales and profits over the next year.
- Customs classification case closed after Rs 0.57 cr paid as duty and interest.
Nureca said it has received closure proceedings from the Commissioner of Customs (NS-V) for the product classification matter flagged by the Directorate of Revenue Intelligence. The Rs 57.12 lakh pre-deposited earlier has been treated as differential duty plus interest and adjusted against the relevant import bills, fully discharging the liability. The company said the matter now stands closed with no further dues under those bills of entry.
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 21 Oct 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2026 and other business matters |
| 21 Jul 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters |
| 29 May 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2026 and other business matters |
| 17 Jan 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2025 and other business matters |
| 28 Nov 2025 | Buyback/Other business matters | To consider buyback for equity shares and other business matters |
| 10 Nov 2025 | Buyback/Other business matters | To consider buyback for equity shares and other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 22 | 17 | 20 | 31 | 26 | 32 | 34 | 38 | 40 | 35 | 40 | 59 |
| Expenses | 27 | 21 | 23 | 34 | 30 | 31 | 35 | 34 | 36 | 41 | 37 | 53 |
| Operating Profit | −4 | −4 | −2 | −2 | −4 | 1 | −1 | 3 | 3 | −6 | 3 | 5 |
| OPM % | −19% | −26.1% | −11.6% | −7.5% | −15.2% | 3.8% | −1.6% | 8.7% | 8.2% | −16.3% | 8.5% | 8.9% |
| Other Income | 6 | −1 | 6 | 3 | 1 | 2 | 3 | 2 | 2 | 1 | 2 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
| Profit before tax | 1 | −6 | 3 | −0 | −3 | 2 | 1 | 5 | 5 | −6 | 4 | 6 |
| Tax % | 82.1% | −35.9% | 36.6% | 585.7% | −13.9% | −20% | 34.2% | 21.1% | 20% | 10.7% | 30.9% | 26.5% |
| Net Profit | 0 | −4 | 2 | −0 | −3 | 2 | 1 | 4 | 4 | −6 | 3 | 4 |
| EPS in Rs | 0.17 | −4.15 | 1.66 | −0.48 | −2.8 | 2.47 | 0.81 | 3.63 | 3.91 | −6.38 | 3.22 | 4.24 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- −7%
- 3 Years
- 10%
- TTM
- 34%
- 10 Years
- —
- 5 Years
- −46%
- 3 Years
- 30%
- TTM
- 16%
- 10 Years
- —
- 5 Years
- −29%
- 3 Years
- −2%
- TTM
- —
- 10 Years
- —
- 5 Years
- 3%
- 3 Years
- −1%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Nureca | ₹ 301.00 | ₹ 305 Cr. | 63.5x | 1.8x | 1% | — |
| Lenskart Solutions | ₹ 627.55 | ₹ 1,08,959 Cr. | 181x | 10.7x | 6.7% | 5.7% |
| Poly Medicure | ₹ 1,446.80 | ₹ 14,582 Cr. | 52.1x | 5.5x | 11% | 17.1% |
| Laxmi Dental | ₹ 171.25 | ₹ 946 Cr. | 35.6x | 5x | 12.8% | 9.5% |
| One Global Service Provider | ₹ 372.00 | ₹ 721 Cr. | 17x | 8.3x | 65.2% | 14% |
| Mallcom (India) | ₹ 909.00 | ₹ 567 Cr. | 21.9x | 2.1x | 9.7% | 5.6% |
Management
- Saurabh Goyal
- Chairman of the Board, Managing Director
- Chander Kant
- Chief Financial Officer
- Nishu Kansai
- Compliance Officer, Company Secretary
- Smita Goyal
- Additional Whole Time Director
- Rajinder Sharma
- Whole Time Director
- Gurvikram Singh
- Assistant Manager - Investors Relations and Corporate Affairs
Prices are delayed and for information only. Nothing on this page is investment advice.